Aardvark Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	39.29	61.64	9.74	15.56
Short-Term Investments	87.07	12.02	0.25	0.55
Cash & Short-Term Investments	126.35	73.66	9.99	16.11
Cash Growth	53.41%	637.44%	-37.98%	-
Prepaid Expenses	2.86	0.31	0.25	0.32
Other Current Assets	-	0.16	0.13	0.07
Total Current Assets	129.21	74.14	10.37	16.49
Property, Plant & Equipment	0.44	0.74	0.16	0.25
Other Long-Term Assets	3.58	2.64	0.01	0.01
Total Assets	133.23	77.51	10.54	16.76
Accounts Payable	4.44	2.3	1.04	0.26
Accrued Expenses	5.86	2.29	0.24	0.24
Current Portion of Leases	0.43	0.34	0.11	0.1
Total Current Liabilities	10.74	4.93	1.38	0.6
Long-Term Leases	0.12	0.44	0.05	0.16
Other Long-Term Liabilities	-	0.03	0	0.02
Total Liabilities	10.85	5.39	1.43	0.78
Additional Paid-In Capital	220.62	3.68	2.94	2.61
Retained Earnings	-98.32	-58.33	-37.74	-30.53
Total Common Equity	122.38	-54.64	-34.8	-27.92
Shareholders' Equity	122.38	72.11	9.1	15.98
Total Liabilities & Equity	133.23	77.51	10.54	16.76
Total Debt	0.55	0.78	0.16	0.26
Net Cash (Debt)	125.81	72.88	9.83	15.84
Net Cash Growth	54.38%	641.67%	-37.97%	-
Net Cash Per Share	8.28	18.24	2.48	4.07
Filing Date Shares Outstanding	21.77	21.7	3.97	3.89
Total Common Shares Outstanding	21.75	4.07	3.97	3.89
Working Capital	118.47	69.21	8.99	15.9
Book Value Per Share	5.63	-13.44	-8.77	-7.18
Tangible Book Value	122.38	-54.64	-34.8	-27.92
Tangible Book Value Per Share	5.63	-13.44	-8.77	-7.18

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q